**Post-progression survival influences overall survival among patients with advanced non-small cell lung cancer undergoing first-line pembrolizumab monotherapy**

Hisao Imai1,2\*, Takayuki Kishikawa3, Hiroyuki Minemura4, Yutaka Yamada5, Tatsuya Ibe6, Keita Mori7, Ou Yamaguchi1, Atsuto Mouri1, Yoichiro Hamamoto6, Kenya Kanazawa4, Takashi Kasai3, Kyoichi Kaira1, Takayuki Kaburagi5, Koichi Minato2, Kunihiko Kobayashi1, Hiroshi Kagamu1

1 Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan

2 Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Gunma, Japan

3 Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

4 Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan

5 Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, Japan

6 Department of Pulmonary Medicine, National Hospital Organization, Nishisaitama-Chuo National Hospital, Tokorozawa, Saitama, Japan

7 Clinical Research Support Center, Shizuoka Cancer Center, Suntou-gun, Shizuoka, Japan

   

**Supplement Fig. 1** Correlation between overall survival (OS) and (**a**) progression-free survival (PFS) and (**b**) post-progression survival (PPS) with recurrence at <6 months. Correlation between OS and (**c**) PFS and (**d**) PPS with recurrence at ≥6 months.

\* *r* represents Spearman’s rank correlation coefficient. \*\* *R2* represents linear regression.

**Supplement Table 1.** Chemotherapeutic regimens used after first-line pembrolizumab monotherapy

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Treatment | Second-line | Third-line | ≥Fourth-line | Total |
| Platinum combination | 24 | 1 | 1 | 26 |
| Single cytotoxic drug |  |  |  |  |
|  Docetaxel | 2 | 3 | 0 | 5 |
|  Pemetrexed | 4 | 1 | 1 | 6 |
|  S-1 | 9 | 4 | 1 | 14 |
|  Others | 0 | 1 | 4 | 5 |
| Docetaxel + ramucirumab | 0 | 4 | 3 | 7 |
| Non-platinum combination | 0 | 0 | 0 | 0 |
| Molecularly-targeted drugs | 0 | 2 | 0 | 2 |
| ICI rechallenge | 0 | 4 | 7 | 11 |
| Beyond administration use | 1 | 0 | 0 | 1 |
| Investigational agent | 0 | 0 | 0 | 0 |
| Best supportive care | 59 | – | – | 59 |

ICI, immune checkpoint inhibitor